Euthymics Bioscience Obtains $3,000,000 New Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=35cb54fa-4c3f-42a6-886d-9c1f9e23efbb&Preview=1 -
Date
11/28/2012 -
Company Name
Euthymics Bioscience -
Mailing Address
43 Thorndike St. Cambridge, MA 02141 -
Company Description
Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics’ initial focus is on patients who do not respond adequately to SSRIs. EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment. -
Website
http://www.Euthymics.com -
Transaction Type
Venture Equity -
Transaction Amount
$3,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. -
M&A Terms
-
Venture Investor
Undisclosed
